The global radiopharmaceuticals third-party logistics (3PL) market is experiencing rapid expansion as nuclear medicine, molecular imaging, and targeted radionuclide therapies become increasingly important in modern healthcare. The specialized nature of radiopharmaceutical transportation is creating strong demand for logistics providers with expertise in time-critical delivery, radiation safety, regulatory compliance, specialized packaging, and temperature-controlled transportation. Unlike conventional pharmaceutical products, radiopharmaceuticals are subject to radioactive decay, making supply-chain efficiency essential for preserving product quality and ensuring timely availability for patients.

The market is projected to expand from USD 1,073.9 million in 2026 to USD 2,913.4 million by 2033, representing a robust CAGR of 15.3% from 2026 to 2033. The rapid expansion of nuclear medicine procedures, growing radiopharmaceutical pipelines, increasing adoption of targeted therapies, and rising outsourcing of specialized logistics activities are creating a favorable environment for third-party logistics providers. North America remains a major market, supported by its established nuclear medicine infrastructure and advanced healthcare ecosystem. 

Download a free sample copy of the Radiopharmaceuticals Third-party Logistics Market report to understand detailed coverage and inclusions in the final report

Key Market Dynamics & Drivers

• Time-Critical Transportation: Radiopharmaceuticals have limited usable lifetimes because their radioactive isotopes decay continuously. This makes transportation speed one of the most important factors in the supply chain. Delays can reduce product effectiveness and increase the risk of product wastage. Consequently, logistics providers are developing specialized just-in-time delivery networks capable of coordinating shipments closely with production and clinical schedules.

• Growing Nuclear Medicine Adoption: Increasing use of PET and SPECT imaging is generating recurring demand for reliable radiopharmaceutical transportation. These diagnostic technologies are increasingly used across oncology, cardiology, neurology, and other medical specialties. As diagnostic procedures increase, healthcare providers require dependable logistics systems that can deliver products within narrow time windows.

• Expansion of Theranostics: The growing adoption of theranostics is creating another major opportunity. Theranostics combines diagnostic imaging with targeted radionuclide therapy, enabling physicians to identify appropriate patients and subsequently deliver targeted treatment. The expansion of radioligand therapies is increasing the need for specialized logistics networks capable of handling both diagnostic and therapeutic radiopharmaceutical products.

• Complex Safety Requirements: Radiopharmaceutical transportation requires specialized radiation protection measures in addition to conventional pharmaceutical handling requirements. Logistics companies must use appropriate shielding, packaging, labeling, documentation, and trained personnel to ensure safe transportation while complying with regulations governing radioactive materials.

Market Segmentation & Highlights

By Type

Diagnostic radiopharmaceuticals maintained a dominant position in the market in 2025, accounting for 65.0% of total revenue. The segment benefits from the widespread use of radiopharmaceuticals in PET and SPECT procedures. Oncology represents a particularly important application because molecular imaging allows healthcare professionals to visualize tumors and assess disease progression.

Therapeutic radiopharmaceuticals are also gaining importance as pharmaceutical companies develop targeted radionuclide therapies for cancer and other diseases. The growing commercial availability of radioligand treatments is expected to increase demand for specialized logistics services capable of managing highly time-sensitive therapeutic shipments. 

By Service Type

Transportation represents a critical component of the radiopharmaceutical 3PL ecosystem. The industry requires a combination of road and air transportation networks to move radioactive products between manufacturing facilities, distribution centers, hospitals, diagnostic centers, and treatment facilities.

Specialized logistics providers are increasingly integrating real-time monitoring, route optimization, GPS tracking, temperature sensors, and digital shipment-management systems to improve delivery visibility and reduce the likelihood of delays. 

By End User

Pharmaceutical and biopharmaceutical companies represent a major source of demand because of the expanding development and commercialization of radiopharmaceutical products. Outsourcing logistics activities allows these companies to access specialized infrastructure without building complete radiation-compliant transportation networks internally.

Regional Outlook

North America held the leading position in the global market in 2025, accounting for 38.1% of total revenue. The region benefits from established nuclear medicine facilities, advanced healthcare infrastructure, strong pharmaceutical research capabilities, and growing adoption of targeted radionuclide therapies.

The U.S. represents the primary contributor to the regional market. Its well-developed radiopharmaceutical production and distribution ecosystem creates strong demand for specialized transportation, cold-chain services, regulatory support, and time-critical delivery.

Asia Pacific represents one of the most promising growth regions. The increasing availability of nuclear medicine services, expanding healthcare infrastructure, rising cancer burden, and development of radiopharmaceutical manufacturing capabilities are supporting regional demand. China, Japan, South Korea, and India are becoming increasingly important markets as healthcare systems invest in advanced diagnostic and therapeutic technologies. 

Core Logistics Capabilities Are Becoming More Specialized

Radiopharmaceutical 3PL providers must deliver significantly more than conventional transportation services. Their operations need to integrate radiation safety, regulatory documentation, temperature management, shipment tracking, specialized packaging, and rapid delivery.

Real-time monitoring is becoming increasingly important because logistics teams need continuous visibility into shipment location and environmental conditions. IoT-enabled sensors can help monitor temperature and shipment status throughout the transportation process.

Radiation-compliant infrastructure is equally important. Specialized containers and shielding systems protect transportation personnel and the surrounding environment while ensuring that products remain secure throughout the journey.

Chain-of-custody management provides another layer of operational control. Accurate documentation and digital tracking help logistics providers maintain shipment visibility and demonstrate compliance with applicable transportation and pharmaceutical regulations.

Looking for more specific insights? Customize this report to suite your business needs

Competitive Landscape & Strategic Developments

Competition in the market is increasingly centered on specialized capabilities rather than conventional transportation scale. Providers are investing in dedicated pharmaceutical logistics networks, temperature-controlled solutions, radiation-compliant packaging, digital tracking systems, and trained personnel.

The expanding radiopharmaceutical pipeline is also encouraging logistics companies to establish stronger relationships with pharmaceutical manufacturers, biotechnology companies, hospitals, nuclear pharmacies, and diagnostic centers. These partnerships can help synchronize production and delivery while reducing delays and product losses.

As more radiopharmaceutical products move from clinical development into commercial use, 3PL companies capable of providing end-to-end specialized logistics are expected to gain an increasing role in the healthcare supply chain.

Future Market Perspective

The future of the radiopharmaceuticals third-party logistics market will be closely connected to the expansion of nuclear medicine and targeted radionuclide therapies. Increasing diagnostic imaging volumes, growing adoption of theranostics, pharmaceutical outsourcing, and investments in radiopharmaceutical manufacturing are expected to generate sustained demand for specialized logistics services.

With the market expected to reach USD 2,913.4 million by 2033 from USD 1,073.9 million in 2026, the industry is positioned for strong expansion at a 15.3% CAGR from 2026 to 2033. The ability to deliver radiopharmaceuticals rapidly, safely, and with complete shipment visibility will remain a critical differentiator as healthcare providers increasingly depend on time-sensitive nuclear medicine products.